Zobrazeno 1 - 10
of 42
pro vyhledávání: '"Deric L. Wheeler"'
Autor:
Mari Iida, Nellie K. McDaniel, Kourtney L. Kostecki, Noah B. Welke, Carlene A. Kranjac, Peng Liu, Colin Longhurst, Justine Y. Bruce, Seungpyo Hong, Ravi Salgia, Deric L. Wheeler
Publikováno v:
BMC Cancer, Vol 22, Iss 1, Pp 1-13 (2022)
Abstract Background The receptor tyrosine kinase (RTK) epidermal growth factor receptor (EGFR) is overexpressed and an important therapeutic target in Head and Neck cancer (HNC). Cetuximab is currently the only EGFR-targeting agent approved by the FD
Externí odkaz:
https://doaj.org/article/f318e0d14cfd458fb59165e96a799ffd
Autor:
Samantha R. Fischbach, Kaitlyn R. Mitchell, Seungpyo Hong, Tamara S. Rodems, Deric L. Wheeler, Alison E. Schulz, Jaimee C. Eckers, Ravi Salgia, Qianyun Luo, Colin Longhurst, Noah B. Welke, Justine Yang Bruce, Nellie K. McDaniel, Carlene A. Kranjac, Amber Bo, Randall J. Kimple, Kwangok P. Nickel, Rong Hu, Meghan M. Gallagher, Mari Iida
Publikováno v:
Clin Cancer Res
Purpose: Radiation and cetuximab are therapeutics used in management of head and neck squamous cell carcinoma (HNSCC). Despite clinical success with these modalities, development of both intrinsic and acquired resistance is an emerging problem in the
Autor:
Mari Iida, Deric L. Wheeler, Hannah E. Pearson, Randall J. Kimple, Rachel A. Orbuch, Nellie K. McDaniel, Kwangok P. Nickel, Jack L. Arbiser
Publikováno v:
Molecular Cancer Therapeutics. 17:204-214
Overexpression and activation of the EGFR have been linked to poor prognosis in several human cancers. Cetuximab is a mAb against EGFR that is used for the treatment in head and neck squamous cell carcinoma (HNSCC) and metastatic colorectal cancer. U
Autor:
Harsh Bahrar, John P. Coan, Toni M. Brand, Johan Lantto, Michael Kragh, Rachel A. Orbuch, Hannah E. Pearson, Deric L. Wheeler, Adam D. Swick, Mari Iida, Prashanth J. Prabakaran, Bailey Flanigan, Randall J. Kimple, Ivan D. Horak, Ravi Salgia
Publikováno v:
Molecular Cancer Therapeutics, 15, 2175-86
Molecular Cancer Therapeutics, 15, 9, pp. 2175-86
Molecular Cancer Therapeutics, 15, 9, pp. 2175-86
Cetuximab, an antibody against the EGFR, has shown efficacy in treating head and neck squamous cell carcinoma (HNSCC), metastatic colorectal cancer, and non–small cell lung cancer (NSCLC). Despite the clinical success of cetuximab, many patients do
Autor:
Kwangok P. Nickel, Jaimee C Eckers-Kubatzke, Prashanth J. Prabakaran, Tamara S. Rodems, Nellie K. McDaniel, Carlene A. Kranjac, Deric L. Wheeler, R.J. Kimple, Mari Iida, Adam D. Swick, Alison E. Schulz, Ravi Salgia, Noah B. Welke
Publikováno v:
Molecular Cancer Therapeutics. 18:A128-A128
Radiation and cetuximab are therapeutics used in the management of head and neck squamous cell carcinoma (HNSCC). Despite clinical success with these modalities, development of both intrinsic and acquired resistance is an emerging problem in the mana
Autor:
Randall J. Kimple, Kwangok P. Nickel, Ravindra Uppaluri, Loren S. Michel, Anthony M. Robinson, Brian A. Van Tine, Douglas Adkins, Nathan J. Redlich, Deric L. Wheeler, Andrew P. Stein
Publikováno v:
Cell Death & Disease
Cell Death and Disease, Vol 9, Iss 1, Pp 1-12 (2018)
Cell Death and Disease, Vol 9, Iss 1, Pp 1-12 (2018)
ErbB3 has been widely implicated in treatment resistance, but its role as a primary treatment target is less clear. Canonically ErbB3 requires EGFR or ErbB2 for activation, whereas these two established treatment targets are thought to signal indepen
Autor:
Toni M. Brand, Andrew P. Stein, Randall J. Kimple, Neha Luthar, Deric L. Wheeler, Mari Iida, Mahmoud Toulany, Ravi Salgia, Cara M. Braverman, Kelsey L. Corrigan, Parkash S. Gill
Publikováno v:
Cancer Research. 74:5152-5164
The EGFR antibody cetuximab is used to treat numerous cancers, but intrinsic and acquired resistance to this agent is a common clinical outcome. In this study, we show that overexpression of the oncogenic receptor tyrosine kinase AXL is sufficient to
Autor:
Rong Hu, Adam D. Swick, Michael M. Fisher, Randall J. Kimple, Amal M. Javaid, Kwangok P. Nickel, Prashanth J. Prabakaran, Mari Iida, Deric L. Wheeler, Emmanuel Sampene, Irene M. Ong, Justine Yang Bruce, Margot C. Miller
Head and neck squamous cell carcinomas (HNSCC) are frequently altered along the PI3K/AKT/mTORC signaling axis. Despite excellent preclinical data, the use of compounds targeting this pathway as monotherapy has been underwhelming in initial clinical t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::afa1a5bf18a478f48e0af5c9c3dac743
https://europepmc.org/articles/PMC5505754/
https://europepmc.org/articles/PMC5505754/
Autor:
Jana Rolff, Randall J. Kimple, Ravi Salgia, Kelsey L. Corrigan, Toni M. Brand, Bailey Flanigan, John P. Coan, Andrew P. Stein, Cara M. Braverman, Mari Iida, Deric L. Wheeler
Publikováno v:
Fed Regist
The epidermal growth factor receptor (EGFR) is a therapeutic target in patients with various cancers. Unfortunately, resistance to EGFR-targeted therapeutics is common. Previous studies identified two mechanisms of resistance to the EGFR monoclonal a
Autor:
Deric L. Wheeler, David T. Yang, Kellie T. Kostopoulos, Mari Iida, Emily F. Dunn, Neha Luthar, Toni M. Brand, Matthew J. Wleklinski, Kelsey L. Corrigan, Kari B. Wisinski, Ravi Salgia
Publikováno v:
Molecular Cancer Therapeutics. 13:1356-1368
Triple-negative breast cancer (TNBC) is a subclass of breast cancers (i.e., estrogen receptor–negative, progesterone receptor–negative, and HER2-negative) that have poor prognosis and very few identified molecular targets. Strikingly, a high perc